Legal Representation
Attorney
Christopher Bennett
USPTO Deadlines
Next Deadline
1951 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20250506)
Due Date
May 06, 2031
Grace Period Ends
November 06, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
30 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 2, 2025 | XXSS | O | GENERIC MADRID TRANSACTION SENT TO IB | Loading... |
| Dec 1, 2025 | XXCR | P | GENERIC MADRID TRANSACTION CREATED | Loading... |
| Sep 12, 2025 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Aug 27, 2025 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Aug 27, 2025 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Aug 6, 2025 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| May 6, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| May 6, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 18, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 18, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 12, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 21, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 21, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 20, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 20, 2025 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Feb 12, 2025 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Feb 12, 2025 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Feb 12, 2025 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Jan 23, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 23, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 23, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 17, 2024 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jul 29, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jul 29, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jun 29, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jun 28, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 27, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 5, 2024 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Apr 1, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 28, 2024 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals, namely, pharmaceutical preparations for supportive treatment and prevention of intestinal diseases, including dysbiosis in the nature of imbalanced microbiota, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), diarrhea, constipation, anorexia, and underweight; Pharmaceuticals, namely, pharmaceutical preparations for supportive treatment and prevention of respiratory diseases, runny nose, nasal congestion, allergic rhinitis, cough, and respiratory infections caused by RSV and influenza virus; Pharmaceuticals, namely, pharmaceutical preparations for supportive treatment and prevention of dental diseases, including tooth decay and periodontitis; Pharmaceuticals, namely, pharmaceutical preparations for supportive treatment and prevention of vaginal disorders, such as itching, irritation, unpleasant odor, abnormal discharge, and discoloration of vaginal secretions; Pharmaceuticals, namely, pharmaceutical preparations for supportive treatment and prevention of skin diseases, including mild to moderate acne, oily skin, and atopic dermatitis; Dietetic foods adapted for medical use; Bio-products for medical purposes, namely, biological preparations for the treatment of supportive treatment and prevention of intestinal diseases, including dysbiosis in the nature of imbalanced microbiota, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), diarrhea, constipation, anorexia, and underweight; Bio-products for medical purposes, namely, biological preparations for the treatment of supportive treatment and prevention of respiratory diseases, runny nose, nasal congestion, allergic rhinitis, cough, and respiratory infections caused by RSV and influenza virus; Bio-products for medical purposes, namely, biological preparations for the treatment of supportive treatment and prevention of dental diseases, including tooth decay and periodontitis; Bio-products for medical purposes, namely, biological preparations for the treatment of supportive treatment and prevention of vaginal disorders, such as itching, irritation, unpleasant odor, abnormal discharge, and discoloration of vaginal secretions; Bio-products for medical purposes, namely, biological preparations for the treatment of supportive treatment and prevention of skin diseases, including mild to moderate acne, oily skin, and atopic dermatitis
Additional Information
Design Mark
The mark consists of the stylized wording LIVESPO with the wording LIVE being in grey and SPO being in dark blue. Below this wording appears the smaller stylized wording A FUTURE WITHOUT ANTIBIOTICS in grey. All the aforementioned appears on a white background.
Color Claim
The color(s) grey, dark blue and white is/are claimed as a feature of the mark.
Other
The color grey appears on the wording "Live" and "A Future Without Antibiotics", the color dark blue appears on the wording "Spo" and the color white is in the background of the mark.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
A FUTURE WITHOUT ANTIBIOTICS